1Hegazy MA, Hegazi RA, Elshafei MA,et al. Neoadjuvant chem- otherapy versus primary surgery in advanced ovarian carcinoma [J]. World J Sur ()neol,2005,3(I) :57 64.
2Bristow R E, Tomacruz R S, Armstrong D K,et al. Survival effect of maximal cytoreductive surgery for advanced ovarian car- cinoma during the platinumera: a meta analysis [J]. J Clin ()n eol,2002,20(5) :1248-1259.
3American Cancer Society. Cancer Facts ~-. Figures for Hispanics [M]. American Cancer Society, 2009: 19-23.
4Hoskins, William J. Principles and practice of gynecologic oncol ogy [J]. Lippincott Williams ~. Wilkins, 2005,6(5) :919-922.
5Elattar A, Bryant A,Winter-Roach BA,et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer E J3. Co chrane Database Syst Rev,2011 ,10(8) : 1231-1233.
6Classc JM,Jaffre 1, Frenel JS, et al. Prognostic factors for pa- tients treated for a recurrenl FIG'() slage 111 ovarittn cancer: a retrospective study of 108 cases [J]. Eur J Surg ()ncol,2011,37 (11):971 977.
7Azzam AZ. Hashad DI, Kamel NAF. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carci- noma:is it time for a step forward [J]. Arch Gynccol Obstet, 2013,288(1) : 167-172.
8Morrison J, Haldar K,Kehoe S,et al. Chemotherapy versus sur- gery for initial treatment in advanced ovarian epithelial cancer [J]. Cochrane Database Syst Rev,2007,6(4) :('D005343.
9Onda T and Yoshikawa H. Neoadjuvant chemotherapy for ad- vanced ovarian cancer: overview of outcomes and unanswered questions [-J~. Expert Rev Anticaneer Ther, 2011,11 (7) : 1055- 1069.
10Kommoss S, Rochon J, Harter P, et el. Prognostic Impact of Ad- ditional Extended Surgical Procedures in Advanced-Stage Prima- ry Ovarian Cancer i-J3. Ann Surg Onco1,17(1):279-286.
